Axsome Thera Cmn Stk (AXSM) 7.69 $AXSM
Axsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
GlobeNewswire - Mon Sep 19, 6:00AM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016 at 8:30 AM Eastern Time. The conference will be held at the Sofitel New York in New York City.
AXSM: 7.69 (+0.20)
Axsome Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Sep 06, 6:00AM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present a corporate overview at the following investor conferences:
AXSM: 7.69 (+0.20)
Axsome Therapeutics Announces Transition of Chief Medical Officer
GlobeNewswire - Fri Sep 02, 3:47PM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced today that Randall Kaye, M.D. is transitioning from his role as Chief Medical Officer (CMO) of the Company to Senior Clinical Advisor, effective September 1, 2016. This new role allows Dr. Kaye to continue to provide his expertise to Axsome while making time for his other medical interests.
AXSM: 7.69 (+0.20)
Axsome Therapeutics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 4:30PM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2016.
AXSM: 7.69 (+0.20)
Axsome Therapeutics (AXSM) Catches Eye: Stock Jumps 6.6%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:40AM CDT
Axsome Therapeutics , Inc. (AXSM) saw its shares above 6% in the last trading session.
ANIP: 64.84 (+1.09), AXSM: 7.69 (+0.20)
Axsome reports 1Q loss
Automated Insights - Wed May 11, 3:48PM CDT
NEW YORK (AP) _ Axsome Therapeutics Inc. (AXSM) on Wednesday reported a loss of $5.9 million in its first quarter.
AXSM: 7.69 (+0.20)
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow Lesions
GlobeNewswire - Tue May 03, 6:01AM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received from the U.S. Food and Drug Administration (FDA) Fast Track designation for AXS-02 for the treatment of the pain of knee osteoarthritis (OA) associated with bone marrow lesions (BMLs). There is currently no product approved specifically for this indication.
AXSM: 7.69 (+0.20)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.42 (+0.06), CBMG: 14.28 (+0.06), OCAT: 8.47 (+0.01), ZBH: 124.79 (-0.18), PFE: 33.81 (+0.16), LLY: 79.88 (+0.72), GSK: 43.06 (-0.24), GLPG: 67.43 (+1.69), AXSM: 7.69 (+0.20), OMER: 11.41 (+0.07), CANF: 2.52 (+0.14), AST: 4.35 (-0.07), AKTX: 9.00 (-0.82)
Axsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimer's Disease
GlobeNewswire - Wed Apr 20, 6:00AM CDT
Phase 2/3 Trial Planned in Agitation in Alzheimer's Disease
AXSM: 7.69 (+0.20)
Axsome Therapeutics to Present at the 2016 BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 6:00AM CST
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference on February 8, 2016 at 9:30 AM Eastern Time. Dr. Tabuteau will provide an overview of Axsome's business and late-stage clinical product candidates, AXS-02 and AXS-05. The conference will be held at the Waldorf Astoria in New York, NY.
AXSM: 7.69 (+0.20)
Axsome Therapeutics to Present at Biotech Showcase 2016
GlobeNewswire - Mon Jan 04, 5:30AM CST
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present at the 8 Annual Biotech Showcase 2016 conference on January 13, 2016 at 10:00 AM Pacific Time. Dr. Tabuteau will provide an overview of Axsome's business and late-stage clinical product candidates, AXS-02 and AXS-05. The conference will be held at the Parc 55 Hotel in San Francisco, CA.
AXSM: 7.69 (+0.20)
Axsome Therapeutics Announces Closing of Initial Public Offering
GlobeNewswire - Tue Nov 24, 3:05PM CST
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced the closing of its initial public offering of 5,666,667 shares of its common stock at a public offering price of $9.00 per share. Axsome Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 850,000 additional shares of common stock at the initial public offering price to cover any over-allotments.
AXSM: 7.69 (+0.20)
Axsome Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Thu Nov 19, 10:39AM CST
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced the pricing of its initial public offering of 5,666,667 shares of its common stock at a public offering price of $9.00 per share. Axsome Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 850,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Capital Market on November 19, 2015, under the symbol "AXSM." The offering is expected to close on November 24, 2015, subject to customary closing conditions.
AXSM: 7.69 (+0.20)
Axsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
GlobeNewswire - Mon Sep 19, 6:00AM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016 at 8:30 AM Eastern Time. The conference will be held at the Sofitel New York in New York City.
AXSM: 7.69 (+0.20)
Axsome Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Sep 06, 6:00AM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present a corporate overview at the following investor conferences:
AXSM: 7.69 (+0.20)
Axsome Therapeutics Announces Transition of Chief Medical Officer
GlobeNewswire - Fri Sep 02, 3:47PM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced today that Randall Kaye, M.D. is transitioning from his role as Chief Medical Officer (CMO) of the Company to Senior Clinical Advisor, effective September 1, 2016. This new role allows Dr. Kaye to continue to provide his expertise to Axsome while making time for his other medical interests.
AXSM: 7.69 (+0.20)
Axsome Therapeutics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 4:30PM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2016.
AXSM: 7.69 (+0.20)
Axsome Therapeutics (AXSM) Catches Eye: Stock Jumps 6.6%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:40AM CDT
Axsome Therapeutics , Inc. (AXSM) saw its shares above 6% in the last trading session.
ANIP: 64.84 (+1.09), AXSM: 7.69 (+0.20)
Axsome reports 1Q loss
Automated Insights - Wed May 11, 3:48PM CDT
NEW YORK (AP) _ Axsome Therapeutics Inc. (AXSM) on Wednesday reported a loss of $5.9 million in its first quarter.
AXSM: 7.69 (+0.20)
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow Lesions
GlobeNewswire - Tue May 03, 6:01AM CDT
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received from the U.S. Food and Drug Administration (FDA) Fast Track designation for AXS-02 for the treatment of the pain of knee osteoarthritis (OA) associated with bone marrow lesions (BMLs). There is currently no product approved specifically for this indication.
AXSM: 7.69 (+0.20)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.42 (+0.06), CBMG: 14.28 (+0.06), OCAT: 8.47 (+0.01), ZBH: 124.79 (-0.18), PFE: 33.81 (+0.16), LLY: 79.88 (+0.72), GSK: 43.06 (-0.24), GLPG: 67.43 (+1.69), AXSM: 7.69 (+0.20), OMER: 11.41 (+0.07), CANF: 2.52 (+0.14), AST: 4.35 (-0.07), AKTX: 9.00 (-0.82)
Axsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimer's Disease
GlobeNewswire - Wed Apr 20, 6:00AM CDT
Phase 2/3 Trial Planned in Agitation in Alzheimer's Disease
AXSM: 7.69 (+0.20)
Axsome Therapeutics to Present at the 2016 BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 6:00AM CST
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference on February 8, 2016 at 9:30 AM Eastern Time. Dr. Tabuteau will provide an overview of Axsome's business and late-stage clinical product candidates, AXS-02 and AXS-05. The conference will be held at the Waldorf Astoria in New York, NY.
AXSM: 7.69 (+0.20)
Axsome Therapeutics to Present at Biotech Showcase 2016
GlobeNewswire - Mon Jan 04, 5:30AM CST
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present at the 8 Annual Biotech Showcase 2016 conference on January 13, 2016 at 10:00 AM Pacific Time. Dr. Tabuteau will provide an overview of Axsome's business and late-stage clinical product candidates, AXS-02 and AXS-05. The conference will be held at the Parc 55 Hotel in San Francisco, CA.
AXSM: 7.69 (+0.20)
Axsome Therapeutics Announces Closing of Initial Public Offering
GlobeNewswire - Tue Nov 24, 3:05PM CST
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced the closing of its initial public offering of 5,666,667 shares of its common stock at a public offering price of $9.00 per share. Axsome Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 850,000 additional shares of common stock at the initial public offering price to cover any over-allotments.
AXSM: 7.69 (+0.20)
Axsome Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Thu Nov 19, 10:39AM CST
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced the pricing of its initial public offering of 5,666,667 shares of its common stock at a public offering price of $9.00 per share. Axsome Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 850,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Capital Market on November 19, 2015, under the symbol "AXSM." The offering is expected to close on November 24, 2015, subject to customary closing conditions.
AXSM: 7.69 (+0.20)
